Soleno Therapeutics Acquisition by Neurocrine Biosciences Completed; Shares Delisted
SLNO sits 80% above its 52-week low of $29.43.
Summary
Soleno Therapeutics announced the completion of its acquisition by Neurocrine Biosciences, with 88.9% of shares tendered, leading to its delisting from Nasdaq.
Key Events · M&A and Partnerships · SLNO
-
Merger Completed
The acquisition of Soleno Therapeutics by Neurocrine Biosciences officially closed on May 18, 2026, making Soleno a direct wholly-owned subsidiary of Neurocrine.
-
Tender Offer Successful
The tender offer expired on May 15, 2026, with 46,356,114 shares, representing approximately 88.9% of outstanding shares, validly tendered and accepted, satisfying the minimum condition.
-
Shares Delisted
All Soleno Therapeutics shares ceased trading on Nasdaq prior to the market open on May 18, 2026, and will be delisted, terminating its public reporting obligations.
Analysis · SLNO · Life Sciences
This filing confirms the successful completion of Neurocrine Biosciences' tender offer for Soleno Therapeutics. With 88.9% of shares tendered, the minimum condition was met, leading to the immediate merger and Soleno becoming a wholly-owned subsidiary. As a result, Soleno's shares have ceased trading on Nasdaq and will be delisted, marking the end of its existence as a publicly traded company.
At the time of this filing, SLNO was trading at $52.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.